Detection of circulating tumour DNA in BRAF V600- mutated advanced melanoma treated with BRAFi or BRAFi plus MEKi

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100045234

Enrollment

Unknown

Registered

2021-04-08

Start date

2021-04-20

Completion date

Unknown

Last updated

2021-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

melanoma

Interventions

single arm:BRAFi or BRAFi plus MEKi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pathologically confirmed patients with BRAF V600- mutated who will be treated with BRAFi or BRAFi plus MEKi.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
ctDNA;curative effect;	—

Countries

China

Contacts

Public ContactChen Ling

Fujian Cancer Hospital & Fujian Medical University Cancer Hospital

fannychenling05@sina.com+86 591 83660063

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026